Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 25 , ISSUE 3 ( March, 2021 ) > List of Articles

EDITORIAL

Tocilizumab in COVID-19: Is the Temptation Worthwhile?

Keywords : Cytokine storm, Tocilizumab, IL-6 blockade

Citation Information : Tocilizumab in COVID-19: Is the Temptation Worthwhile?. Indian J Crit Care Med 2021; 25 (3):247-248.

DOI: 10.5005/jp-journals-10071-23750

License: CC BY-NC 4.0

Published Online: 20-03-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis 2020;71(8):1937–1942. DOI: 10.1093/cid/ciaa449.
  2. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2(8):e474–e484. DOI: 10.1016/S2665-9913(20)30173-9.
  3. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang Lu, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020;ciaa954. DOI: 10.1093/cid/ciaa954.
  4. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol 2020;2(10):e603–e612. DOI: 10.1016/S2665-9913(20)30277-0.
  5. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al; for the STOP-COVID Investigators. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med 2021;181(1):41–51. DOI: 10.1001/jamainternmed.2020.6252.
  6. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19(7):102568. DOI: 10.1016/j.autrev.2020.102568.
  7. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al; for the RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard of care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med 2021;181(1):24–31. DOI: 10.1001/jamainternmed.2020.6615.
  8. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; for the CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2021;181(1):32–40. DOI: 10.1001/jamainternmed.2020.6820.
  9. Rosas I, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. MedRxiv 2020.08.27.20183442. DOI: 10.1101/2020.08.27.20183442.
  10. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients admitted with Covid-19 pneumonia. N Engl J Med 2021;384:20–30. DOI: 10.1056/NEJMoa2030340.
  11. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020;383:2333–2344. DOI: 10.1056/NEJMoa2028836.
  12. Rankawat G, Bhandari S, Singh A. Tocilizumab: an effective therapy for severe and critical ill COVID 19 patients. Indian J Crit Care Med 2021;25(3):260–266.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.